Fractyl Health reports early REVEAL-1 data suggests Revita prevents weight regain after GLP-1 stop

FRACTYL HEALTH, INC.

First 7 patients showed average weight regain of 1.2% at 1 month vs typical ~3% after GLP-1 discontinuation.
No safety or tolerability concerns in 15 patients treated to date; consistent with prior pooled data.
REMAIN-1 pivotal study now >50% enrolled; full enrollment expected summer 2025; midpoint analysis Q3 2025.
Revita holds FDA Breakthrough Device designation for post-GLP-1 weight maintenance.
Additional REVEAL-1 follow-up data expected in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.